Floatz logo

Hynr-Cs-Allo

Neuromuscular Disease

Hanyang University Seoul HospitalCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Neuromuscular Disease cohort.

Asset / SponsorPhaseRating
Apitegromab
Scholar Rock, Inc.
Phase 3BB
Ataluren
PTC Therapeutics
Phase 3B
Taldefgrobep Alfa
Biohaven Pharmaceuticals, Inc.
Phase 3B
Aoc 1044
Avidity Biosciences, Inc.
Phase 3B
Zeleciment Rostudirsen
Dyne Therapeutics
Phase 3B

View all 16 →

Same molecule, other indications

Hynr-Cs-Allo is also rated in:

neurodegeneration with brain iron accumulationDormant
CC
Indicative · Phase 1
47 / 100
View asset →
central nervous system disorderDormant
CC
Indicative · Phase 1
47 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative · Phase 1
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →